FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSIO Washington, D.C. 20549
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

		of Section So(n) of the investment Company Act of 1940					
1. Name and Address of Reportin Boral Anthony L.	ng Person*	2. Issuer Name and Ticker or Trading Symbol <u>Blueprint Medicines Corp</u> [BPMC]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Conternational State St				
(Last) (First) C/O BLUEPRINT MEDIC 45 SIDNEY STREET	(Middle) INES CORPORATION	3. Date of Earliest Transaction (Month/Day/Year) 12/14/2020	Chief Medical Officer				
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150. 4)
Common Stock	12/14/2020		M ⁽¹⁾		10,000	A	\$15.01	38,147	D	
Common Stock	12/14/2020		S ⁽¹⁾		7,815	D	\$118.72 ⁽²⁾	30,332	D	
Common Stock	12/14/2020		S ⁽¹⁾		1,970	D	\$117.92 ⁽³⁾	28,362	D	
Common Stock	12/14/2020		S ⁽¹⁾		215	D	\$116.75	28,147	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				6. Date Exerc Expiration Da (Month/Day/)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$15.01	12/14/2020		M ⁽¹⁾			10,000	(4)	02/03/2026	Common Stock	10,000	\$0	7,483	D	

Explanation of Responses:

1. Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$118.32 to \$119.315 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this form 4.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$117.39 to \$118.30 per share.

4. This option was granted on February 3, 2016. This option is fully vested as of the date hereof.

/s/ Christopher Frankenfie	eld,
Attorney-in-Fact	

** Signature of Reporting Person Date

12/16/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

CEC E 4

1

COMMISSION

3235-0287

Estimated average burden hours per response: 0.5

OMB APPROVAL

OMB Number: